Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Strategies for Juvenile Idiopathic Arthritis Patients With Sustained Inactive Disease: A Phase 4, Multicentre, Randomised Trial Comparing Maintenance Versus Tapered TNF Alpha Inhibitor Monotherapy - the Treat-JIA Trial

NCT07904780 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07904780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Strategies for Juvenile Idiopathic Arthritis Patients With Sustained Inactive Disease: A Phase 4, Multicentre, Randomised Trial Comparing Maintenance Versus Tapered TNF Alpha Inhibitor Monotherapy - the Treat-JIA Trial
Lead sponsor
Oslo University Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
November 11, 2026
Completion date
November 11, 2030
Enrollment
90 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile idiopathic arthritis (jia)

Arms

As registered; 2 arms.

  • Stable TNF-inhibitor monotherapy Active comparatorAdalimumab, Etanercept, Golimumab

    Continued TNF-inhibitor therapy at a stable dose. This can be adalimumab, etanercept or golimumab.

  • TNF-inhibitor withdrawal ExperimentalAdalimumab, Etanercept, Golimumab

    Doubled treatment interval of the TNF-inhibitor therapy for 4 months, then subsequent withdraw of the TNF-inhibitor therapy.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Proportion of disease flare 4, 8 and 12 months

    Disease flare is defined as a combination of: A clinical significant increase in Juvenile Arthritis Disease Activity Score 27 (JADAS-27\*) ≥1.7 from baseline AND active joints ≥1 (swollen, or tender + limited range of motion) OR consensus between treating physician and participant/parents that a clinically significant flare has occurred with need of intensification of antirheumatic treatment.

Lead sponsor's other trials

Oslo University Hospital, most recent start first.

Similar trials

Same condition (Arthritis, Juvenile) and phase, most recent start first.